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Abstract  
The majority of glioblastomas develop rapidly with a short clinical history (primary 
glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse 
astrocytoma or anaplastic astrocytoma. IDH mutations are the genetic hallmark of 
secondary glioblastomas. Gliosarcomas and giant cell glioblastomas are rare 
histological glioblastoma variants, which usually develop rapidly. We determined the 
genetic patterns of 36 gliosarcomas and 19 giant cell glioblastomas. IDH1 and IDH2 
mutations were absent in all 36 gliosarcomas and in 18 of 19 giant cell glioblastomas 
analyzed, indicating that they are histological variants of primary glioblastoma. 
Furthermore, LOH 10q (88%) and TERT promoter mutations (83%) were frequent in 
gliosarcomas. Copy number profiling using the 450k methylome array in 5 
gliosarcomas revealed CDKN2A homozygous deletion (3 cases), trisomy 
chromosome 7 (2 cases), and monosomy chromosome 10 (2 cases). Giant cell 
glioblastomas had LOH 10q in 50% and LOH 19q in 42% of cases. ATRX loss was 
detected immunohistochemically in 19% of giant cell glioblastomas, but absent in 17 
gliosarcomas. These and previous results suggest that gliosarcomas are a variant of, 
and genetically similar to, primary glioblastomas, except for a lack of EGFR 
amplification, while giant cell glioblastoma occupies a hybrid position between 
primary and secondary glioblastomas. 
 
 
INTRODUCTION 
Glioblastoma (WHO grade IV) is the most frequent and malignant glioma. The 
majority of glioblastomas (>90%) develop rapidly after a short clinical history, without 
evidence of a less malignant precursor lesion (primary glioblastoma). In contrast, 
secondary glioblastomas develop through progression from diffuse astrocytoma 
(WHO grade II) or anaplastic astrocytoma (WHO grade III) (24, 27, 28). The decisive 
genetic alterations that reliably distinguish between primary and secondary 
glioblastoma are IDH mutations (3, 24, 28, 35, 37) which constitute a reliable genetic 
marker of secondary glioblastoma. In a large population-based study, IDH1 mutation 
status corresponded to the respective clinical diagnosis in 95% of cases (24, 28).  
 Gliosarcoma and giant cell glioblastoma are rare histological variants of 
glioblastoma (16). On clinical grounds, they are considered variants of primary 
glioblastoma, but genetic data that would allow an unambiguous classification are still 
scant. Gliosarcomas constitute approximately 2% of all glioblastomas (16), and are 
characterized by a biphasic tissue pattern with alternating areas displaying glial or 
mesenchymal differentiation (16). Despite these two distinct histological components, 
gliosarcomas are considered monoclonal, since glial and mesenchymal tumor areas 
were usually found to be genetically similar (4, 31). It has been reported that PTEN 
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mutations (37-45%) and p16INK4a homozygous deletion (37%) are common, TP53 
mutations (24-26%) less frequent, and EGFR amplification rare or absent (0-8%) (1, 
31).  
 Giant cell glioblastomas constitute up to 5% of all glioblastomas, and are 
characterized by a predominance of bizarre, multinucleated giant cells with an 
occasionally abundant reticulin network (16). TP53 mutations are frequent (78–90%) 
and PTEN mutations are common (33%), but EGFR amplification and p16INK4a 
homozygous deletion have been reported to be rare (17, 18, 30).  
 The objectives of the present study are to further genetically characterize these 
glioblastoma variants. We screened 36 gliosarcomas and 19 giant cell glioblastomas 
for IDH1 and IDH2 mutations (genetic hallmarks of secondary glioblastoma), and 
various additional genetic alterations known to be operative in diffuse gliomas. 
 
MATERIALS AND METHODS 
Tumor samples  
Formalin-fixed and paraffin embedded tissue samples of 36 gliosarcomas were 
obtained from the Neurological Institute (Edinger Institute), University Hospital 
Frankfurt, Germany, the Institute of Neuropathology, University Hospital Munster, 
Germany, the Department of Neuropathology, University Hospital Rome, Italy, the 
Institute of Neuroscience, Bordeaux, France, and the Department of Neuropathology, 
University Hospital Zurich, Switzerland. Formalin-fixed tissue samples of 19 giant cell 
glioblastomas, as well as a frozen sample of a giant cell glioblastoma were obtained 
from the Department of Neuropathology, University Hospital Zurich, Switzerland, the 
Institute of Neuropathology, University Hospital Munster, Germany, and the 
Departments of Neuropathology and Neurosurgery, University Hospital Essen, 
Germany.  
 Gliosarcomas and giant cell glioblastomas were diagnosed according to the 2007 
WHO Classification (16). Histologically, gliosarcomas showed the typical biphasic 
pattern with alternating areas of glial and mesenchymal differentiation (Fig. 1A). The 
glial area was composed of anaplastic glial cells with GFAP expression, and the 
mesenchymal component demonstrated bundles of spindle cells with malignant 
transformation and abundant connective tissue stained by reticulin, without GFAP 
expression (Fig. 1B). For selection of giant cell glioblastomas, care was taken to 
include only typical cases showing a predominance of multinucleated, GFAP positive 
tumor cells in at least one large area of the biopsy specimen. All gliosarcomas and 18 
giant cell glioblastomas were located in cerebral hemispheres; one giant cell 
glioblastoma was in the thalamus. This study was approved by the International 
Agency for Research on Cancer (IARC) Ethics Committee. 
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DNA extraction  
Genomic DNA was extracted from typical tumor areas that were scraped from 
formalin-fixed and paraffin-embedded tissue slides or cryostat section from a frozen 
sample as previously described (23, 29). DNA concentration and purity were 
measured by a ND8000 spectrophotometer (NanoDrop Technologies, Wilmington, 
DE, USA). 
 
IDH mutations 
Screenings for the IDH1 and IDH2 mutations were performed in 36 gliosarcomas and 
19 giant cell glioblastomas by Sanger sequencing as described previously (24, 35).  
 
TERT promoter mutations 
Sequences covering the mutational hotspots (C228T and C250T) in the TERT core 
promoter were amplified by nested PCR. Primer sequences and detailed protocols 
were reported previously (25). We considered as TERT mutations only cases when 
the height of the mutated allele was >20% of that of the wild-type allele on 
sequencing data, as previously described (25).  
 
LOH 1p, 19q, 10q 
Quantitative PCR was performed to assess LOH 1p, 19q, and 10q in 17 
gliosarcomas and 12 giant cell glioblastomas. Microsatellite markers were D1S214, 
D1S468, and D1S2736 at 1p36.32-1p36.22, D19S408, D19S596, and D19S867 at 
19q13.31-19q13.33, D10S536 at 10q23.3, and D10S1683 at 10q24.2 (22, 26). We 
interpreted as LOH when 2 or 3 markers for each chromosome suggested loss, as 
described previously (22, 26).  
 
ATRX immunohistochemistry 
ATRX immunohistochemistry was carried out in 17 gliosaromas and in 16 giant cell 
glioblastomas. Paraffin sections were deparaffinized in xylene and 95% ethanol for 5 
min. After inactivation of endogenous peroxidases with 3% of H2O2 in methanol for 30 
min, sections were incubated in epitope retrieval solution (diluted 1:10, H-3300, Low 
pH 6.0, Vector Laboratories, inc. Burlingame, CA, USA) for 20 min at 95 – 99°C. 
Sections were cooled for 40 min at room temperature, and were incubated with anti-
ATRX antibody (1:400, HPA001906, rabbit polyclonal, Sigma-Aldrich, St. Louis, MO, 
USA), diluted in antibody diluent (S3022, Dako, Les Ulis, France) at 4°C overnight. 
Sections were then washed in phosphate buffered saline (PBS) and incubated with 
the second antibody (EnVision+Single Reagents HRP rabbit, K4002, Dako, Les Ulis, 
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France) for 30 min. Visualization was performed using Vector DAB Substrate Kit (SK-
4100; Vector Laboratories) for 4 min. After washing in PBS, sections were 
counterstained with hematoxylin.  
 For optimization of immunohistochemistry protocols, normal human brain tissue 
was used as a positive control, and human liver tissue was used as a negative 
control. For interpretation of ATRX immunoreactivity, vascular endothelial cells within 
tumor tissues on histological slides were used as internal positive controls. Cases 
with more than 10% immunoreactive tumor cells were considered as positive as 
previously described (36) 
 
Methylome and copy number profiling 
The Illumina Infinium HumanMethylation450 (450k) array was used in 5 
gliosarcomas, for which sufficient DNA from paraffin sections were available, to 
obtain the DNA methylation status of 482,421 CpG sites (Illumina, San Diego, CA, 
USA), according to the manufacturer’s instructions at the Core Facility of the DKFZ. 
The methylation level of each CpG site was represented by beta-values, which 
ranged from 0 (unmethylated) to 1 (methylated). Genome-wide copy-number profiles 
were calculated by using the intensity measures of the aforementioned methylation 
probe loci throughout the genome. Chromosomal copy-number alterations were 
visualized by the IdeogramBrowser tool (19).  
 
Statistical analysis 
Fisher exact test was performed to evaluate the significance of difference in various 
genetic alterations. The significance level chosen was P < 0.05. Statistical analyses 
were carried out using Stat View J-5.0 software (Abacus Concepts, Berkeley, CA, 
USA). 
 
RESULTS 
IDH mutations 
IDH1 mutations were absent in all 36 gliosarcomas and in 18 out of 19 giant cell 
glioblastomas analyzed. One giant cell glioblastoma with an IDH1 (R132S) mutation 
was diagnosed in a 44 year-old male patient, who developed anaplastic astrocytoma 
one year earlier. TP53 mutation (R280T) was also detected in both anaplastic 
astrocytoma and giant cell glioblastoma. IDH2 mutations were absent in all 
gliosarcomas and giant cell glioblastomas analyzed.  
 
TERT promoter mutations 
TERT promoter mutations were detected in 30 of 36 (83%) gliosarcomas. Of these, 
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76% were C228T and 24% were C250T. This ratio was similar to that reported in 
primary glioblastomas (25).  
 For the 20 selected gliosarcomas, we carried out screening for TERT promoter 
mutations separately in glial and mesenchymal components, and found identical 
results in 19 cases. In one gliosarcoma, TERT mutation was observed in only the 
mesenchymal component, but not in the glial component. 
 TERT promoter mutations (C228T) were found in 4 of 16 (25%) giant cell 
glioblastomas.  
 
LOH 1p, 19q, 10q 
Quantitative PCR revealed LOH 1p in 1 / 17 (6%) gliosarcomas and in 2 of 12 (17%) 
giant cell glioblastomas. LOH 19q was detected in 3 gliosarcomas (3/17; 18%) and 5 
giant cell glioblastomas (5/12; 42%). LOH 10q was detected in 15 / 17 gliosarcomas 
(88%) and in 6 of 12 (50%) giant cell glioblastomas. Co-deletion of 1p/19q was 
detected in 1/17 (6%) gliosarcomas and in 2/12 (17%) giant cell glioblastomas.   
 
ATRX immunohistochemistry 
Loss of nuclear ATRX expression was observed in 3 of 16 (19%) giant cell 
glioblastoma, but in none of the 17 gliosarcomas analyzed.  
 ATRX was expressed in vascular endothelial cells (internal positive control) in all 
histological sections. Sections without ATRX antibodies showed no immunoreactivity. 
 
Copy number profiling  
Copy number plots generated from 450k methylation data in 5 gliosarcomas revealed 
CDKN2A homozygous deletion (3 cases), monosomy chromosome 10 (2 cases), 
trisomy chromosome 7 (2 cases), gain at chromosome 7 (one case), and CDK4 
amplification (one case).  
 
Comparison of genetic alterations with primary and secondary glioblastomas  
Genetic alterations of the gliosarcomas and giant cell glioblastomas which were 
obtained in the present study as well as those reported previously are summarized in 
Table 1. These data were compared with those of the primary glioblastomas (IDH-
wild-type) and secondary glioblastomas (IDH mut) reported previously (Table 1) (24, 
25).  
 PTEN mutations in gliosarcomas (41%) were significantly more frequent than 
those in primary glioblastomas (24%; P = 0.0190) and in secondary glioblastomas 
(5%; P = 0.0001). Loss of ATRX expression was less frequent in gliosarcomas than 
secondary glioblastomas (P = 0.0009). TERT promoter mutations in gliosarcomas 
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were more frequent (83%) than those in secondary glioblastomas (26%; P < 0.0001). 
LOH 19q was more frequent in gliosarcomas (18%) than those in primary 
glioblastomas (4%; P = 0.0406). LOH 10q was more frequent in gliosarcomas (88%) 
than those in primary glioblastomas (67%; P = 0.0452).  
 PTEN mutations in giant cell glioblastomas (33%) were significantly more 
frequent than those in secondary glioblastomas (5%; P = 0.0126). Loss of ATRX 
expression was less frequent in giant cell glioblastomas than in secondary 
glioblastomas (P = 0.0206). TP53 mutations were more frequent in giant cell 
glioblastomas (84%) than in primary glioblastomas (23%; P < 0.0001). LOH 19q was 
more frequent in giant cell glioblastomas (42%) than in primary glioblastomas (4%; P 
= 0.0002; Table 1).  
 
DISCUSSION 
IDH1 mutations are the definitive molecular marker of secondary glioblastoma (24, 
28). Gliosarcomas and giant cell glioblastomas usually develop rapidly without less 
malignant precursor lesions (31), and have thus been considered to be primary 
glioblastomas. There have been few studies on IDH mutations. Lee et al. (13) 
screened 26 gliosarcomas (21 primary gliosarcomas, 2 progressed from grade II or 
grade III astrocytomas, 2 developed from glioblastomas; one developed 9 years after 
radiotherapy for meningioma) for IDH1 mutations. IDH1 mutations were detected in 
one primary gliosarcoma and in a secondary gliosarcoma that progressed from a 
grade III astrocytoma (13). Balss et al. (3) reported that 2 of 8 giant cell glioblastomas 
but none of 5 gliosarcomas carried IDH1 mutations. Lotsch et al. (15) reported the 
absence of IDH1 mutations in one gliosarcoma and one giant cell glioblastoma.  
 This study provides evidence that gliosarcoma is indeed a histological variant of 
primary glioblastoma IDH wild-type. IDH1 and IDH2 mutations were absent in all 36 
gliosarcomas analyzed. TERT promoter mutations, which are frequent in primary 
glioblastomas (2, 25), were detected in 83% of gliosarcomas (Table 1). Furthermore, 
LOH 10q was observed in 15/17 (88%) gliosarcomas. Monosomy of chromosome 10 
was also observed in 2/5 gliosarcomas in analysis calculated from 450k methylome 
array. Immunohistochemistry showed that ATRX is expressed in all gliosarcomas, 
suggesting the absence of ATRX mutations (14, 36). Thus, gliosarcomas share 
clinical and genetic features with primary glioblastomas IDH wild-type. The only major 
difference was EGFR amplification, which is common in primary glioblastomas and 
was considered to be a rare event in gliosarcomas (1, 31) (Table 1).  
 Despite two distinct histological components, gliosarcomas are considered 
monoclonal, since glial and mesenchymal tumor areas were usually found to be 
genetically similar with respect to TP53 mutations, PTEN mutations, p16INK4a 
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deletion, EGFR amplification, and 10q loss (4, 31). The present study shows that this 
is also the case for TERT promoter mutations, as they were present in both glial and 
mesenchymal tumor areas in 95% (19/20) of gliosarcomas.  
 The molecular mechanisms involved in the mesenchymal differentiation in 
gliosarcomas are not yet fully understood. Expression of several transcription factors 
(e.g. Slug, Twist, MMPs) associated with epithelial-mesenchymal transition (EMT), 
was found in mesenchymal tumor areas, suggesting that signalling pathways 
involved in EMT may play a role in the induction of mesenchymal differentiation (21). 
In studies using conventional CGH, patterns of chromosomal imbalance were largely 
similar in glial and mesenchymal tumor areas, but there were also gains and losses 
at several loci unique to either glial or mesenchymal tumor areas (1, 6). Using array 
CGH, we have shown that in a small fraction of gliosarcomas the gain at 13q13.3-
q14.1 and expression of several genes (STOML3, FREM2, LHFP) at this locus was 
restricted to the mesenchymal tumor area of gliosarcomas (20).  
 Giant cell glioblastomas develop rapidly with a short clinical history, but they 
occur in young adults (mean, 44 years), similar to secondary glioblastomas IDH mut 
(18, 30). We here provide genetic evidence that giant cell glioblastoma is a 
histological variant of primary glioblastoma IDH wild-type as IDH1/2 mutations were 
absent in 18 of 19 giant cell glioblastomas analyzed. However, frequencies of TERT 
promoter mutations, TP53 mutations, LOH 19q, and EGFR amplification were similar 
to those of secondary IDH1 mut glioblastomas (17, 18, 30) (Table 1). Thus, giant cell 
glioblastoma occupies a hybrid position, sharing with primary glioblastoma a short 
clinical history, the absence of less malignant lesions, absence of IDH1/2 mutations, 
frequent PTEN mutations and infrequent ATRX loss. In common with secondary 
glioblastomas, they have a younger patient age at manifestation, infrequent TERT 
promoter mutations, frequent TP53 mutations, frequent LOH 19q, and lack of EGFR 
amplification. 
 There was the exceptional case of a giant cell glioblastoma IDH1 mut (R132S) 
with clinical evidence suggesting progression from an anaplastic astrocytoma 
diagnosed a year earlier. This suggests that rarely, a secondary glioblastoma may 
show the histologic features of a giant cell glioblastoma.  
 The molecular mechanisms involved in the giant cell phenotype are not yet fully 
understood. Temme et al. (34) reported that Aurora B expression is significantly 
higher in giant cell glioblastomas than in other glioblastomas, and that ectopic 
overexpression of Aurora B induced a significant increase in the proportion of 
multinucleated giant cells in TP53 mutant but not in TP53 wild-type malignant glioma 
cells.   
 LOH 10q is a frequent genetic alteration in both primary and secondary 
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glioblastomas, suggesting that this chromosomal region may contain tumor 
suppressor gene(s), essential for malignant glioblastoma phenotype (27, 28). LOH 
10q is also associated with shorter survival of glioblastoma patients in both 
population based (24, 26) and hospital-based studies (7, 33). We here provide 
evidence that LOH 10q is the genetic hallmark of gliosarcomas (88%) and giant cell 
glioblastomas (50%), further suggesting that gene(s) at 10q play an important role in 
the pathogenesis of glioblastomas and their variants.   
 In summary, gliosarcomas and giant cell glioblastomas are both histological 
variants of primary glioblastoma IDH1 wild-type. The genetic pattern of gliosarcoma 
is largely similar to that of primary glioblastoma except for a lack of EGFR 
amplification, while giant cell glioblastoma genetically occupies a hybrid position 
between primary and secondary glioblastomas.  
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Legend to Figures:  
 
Fig. 1 
 
Gliosarcomas showing the typical biphasic pattern with alternating areas of glial and 
mesenchymal differentiation (A). Note that the glial area was composed of anaplastic 
glial cells with GFAP expression, while mesenchymal component lacks GFAP 
expression (B). Giant cell glioblastoma with multinucleated giant cells (C). GFAP is 
expressed at different levels in multinucleated giant cells in giant cell glioblastoma 
(D). Multinucleated giant cells with loss of nuclear ATRX expression in giant cell 
glioblastoma (E). Another giant cell glioblastoma showing nuclear immunoreactivity to 
ATRX (F). Arrows indicate nuclear ATRX expression in endothelium served as an 
internal positive control. 
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Table 1 Clinical and genetic profile of the gliosarcoma and the giant cell glioblastoma, in comparison with 
primary and secondary glioblastoma 
  
Primary glioblastoma 
(IDH wild-type) 
 Gliosarcoma  
Giant cell 
glioblastoma 
 
Secondary glioblastoma 
(IDH mutant) 
             
Age at GBM diagnosis 59 years1,2,3,4  56 years5  44 years6,7  43 years1,2,3,4 
Sex ratio M/F 1.41,2  1.45  1.66  1.01,2 
Clinical history 3.9 months1  3.0 months5  1.6 months6  15.2 months1 
             
IDH1/2 mutation 0%1,8,9  0%*  5%*  100%1,8,9 
PTEN mutation 24%1,8,9  41%5,10  33%6  5%1,8,9 
ATRX expression loss 0%11  0%*  19%*  100%11 
TERT mutation 72%12,13,14  83%*  25%*  26%12,13,14 
TP53 mutation 23%1,8,9  25%5,10  84%6,7,15  74%1,8,9 
LOH 19q 4%1  18%*  42%*  32%1 
EGFR amplification 42%1,8,9  5%5,10  6%6,7,15  4%1,8,9 
p16INK4a deletion 45%1,8,9  37%5  3%6,7  30%1,8,9 
LOH 1p 15%1  6%*  17%*  24%1 
LOH 1p/19q 2%1  6%*  17%*  11%1 
LOH 10q 67%1  88%*  50%*  73%1 
        
* This study; 
1Nobusawa et al. (24); 2Bleeker et al. (5);  3Ichimura et al. (12); 4Reuss et al. (32); 5Reis et al. (31); 6Peraud et al. (30);  7Meyer-
Puttlitz et al. (18); 8Gao et al. (11); 9Cerami et al. (9); 10Actor et al. (1); 11Liu et al. (14); 12Nonoguchi et al. (25);  13Eckel-Passow et al. 
(10); 14Brennan et al. (8); 15Martinez et al. (17)  
 
 Typical for primary glioblastomas 
 Typical for secondary glioblastomas 
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